Eton Pharmaceuticals, Inc. (ETON) fair value analysis
Nasdaq · Updated 2026-10-19
ETON price how computed
Valuation status
Awaiting full valuationETON does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards.
We require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $50.31
- Sector
- Healthcare
- 12-month range
- $14.35–$64.43
- Market cap
- $1.44B
- From 52-week high
- -21.9%
- Shares outstanding
- 28.6M
- Rank in Healthcare by quality score
- #51 of 301
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Eton Pharmaceuticals, Inc. is a pharmaceutical company that develops and commercializes specialty drugs focused on treating rare and orphan diseases. The company operates in the United States.
ETON currently ranks #51 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $1.44B
- P/E (trailing)
- 70x
- Revenue (TTM)
- $106M
- Net margin
- 12.0%
- EPS (TTM)
- $0.72
- Gross margin
- 67.6%
- Debt / equity
- 0.62
- Revenue growth (3-yr avg)
- 144.9%
- Shares outstanding
- 28.6M
Derived indicators how computed
- Quality grade
- B
- Margin trend
- Contracting
- 52-week position
- The upper-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 36 · neutral
- 50-day average
- $56.21
- 200-day average
- $33.98
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-05
- Last 8 quarters vs consensus
- 3 beat, 4 missed
- Quarter by quarter
- 2026-06 ▲ beat (+218.2%)
2026-03 ▬ met (0.0%)
2025-12 ▲ beat (+5.6%)
2025-09 ▼ miss (-75.0%)
2025-06 ▼ miss (-900.0%)
2025-03 ▼ miss (-220.0%)
2024-12 ▼ miss (-506.1%)
2024-09 ▲ beat (+300.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 4 buy · 0 hold · 0 sell (4 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $71.5
- Target vs last price
- +42.1%
What our data shows for ETON
- Our model validated 3 trailing price-to-earnings windows for ETON, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $14.35–$64.43.
- The 14-day relative strength index sits at a neutral 36.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- ETON's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent ETON news
TickrTrends' derived news-sentiment signal for ETON is currently leaning positive, computed from recent coverage.
- Eton Pharmaceuticals Inc (ETON) Shares Fall 3.5% -- GF Value Says Still Overvalued (gurufocus.com, 2026-10-13)
- Eton Pharmaceuticals Inc (ETON) Shares Fall 13.0% -- What GF Score of 65 Tells Investors (gurufocus.com, 2026-10-01)
- Eton Pharmaceuticals (ETON) Launches Impavido Capsules, Expanding U.S. Market Presence (gurufocus.com, 2026-09-28)
What people are saying
Follow the ETON conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — ETON, a healthcare sector stock, experienced notable shifts in its derived indicators this week. The 50/200-day trend state moved from uptrend to mixed, while the quality grade declined from A to B. The current valuation verdict for ETON remains awaiting full valuation.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is ETON stock undervalued?
ETON does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is ETON's TickrTrends verdict?
ETON is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
How does ETON compare to other Healthcare stocks?
ETON ranks #51 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is ETON overbought or oversold?
ETON's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does ETON report earnings next?
ETON's next earnings report is scheduled for 2026-11-05, per the published earnings calendar.
Does ETON usually beat earnings estimates?
Over its last 8 reported quarters ETON beat the consensus estimate 3 times and missed 4 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about ETON?
Of 4 analysts covering ETON, 4 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $71.5 (+42.1% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.